Document:

Exhibit 4.8

Description of the Registrant’s
Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

 

As of December 31, 2020, Augmedix, Inc. (the “Company,”
“we,” or “our”) had one class of securities registered under Section 12 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”): our common stock.

The following description summarizes the
most important terms of our capital stock and certain provisions of our restated certificate of incorporation and restated bylaws. Because
it is only a summary, it does not contain all of the information that may be important to you. For a complete description, you should
refer to our restated certificate of incorporation and restated bylaws, which are incorporated by reference as an exhibit to the Annual
Report on Form 10-K of which this Exhibit 4.8 is a part, and to the provisions of applicable Delaware law.

Authorized Capital Stock

Our authorized capital stock consists of 500,000,000 shares of common
stock, $0.0001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.0001 par value per share.

Common Stock 

Dividend Rights 

Subject to preferences that may apply to any shares of preferred
stock outstanding at the time, the holders of our common stock are entitled to receive dividends out of funds legally available if our
board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors
may determine. See the section entitled “Dividend Policy.”

Voting Rights 

Holders of our common stock are entitled to one vote for each
share held on all matters submitted to a vote of stockholders. We have not provided for cumulative voting for the election of directors
in our restated certificate of incorporation, which means that holders of a majority of the shares of our common stock will be able to
elect all of our directors. Our restated certificate of incorporation established a classified board of directors, divided into three
classes with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with
the other classes continuing for the remainder of their respective three-year terms.

No Preemptive or Similar Rights 

Our common stock is not entitled to preemptive rights, and is not
subject to conversion, redemption or sinking fund provisions.

Right to Receive Liquidation Distributions 

Upon our liquidation, dissolution or winding-up, the assets legally
available for distribution to our stockholders would be distributable ratably among the holders of our common stock and any participating
preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights
of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.

 

    1

     

    

Preferred Stock 

Our board of directors is authorized, subject to limitations prescribed
by Delaware law, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time the number
of shares to be included in each series and to fix the designation, powers, preferences and rights of the shares of each series and any
of their qualifications, limitations or restrictions, in each case without further vote or action by our stockholders. Our board of directors
is also able to increase or decrease the number of shares of any series of preferred stock, but not below the number of shares of that
series then outstanding and not above the number of shares of that series authorized, without any further vote or action by our stockholders.
Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the
voting power or other rights of the holders of our common stock. The issuance of preferred stock, while providing flexibility in connection
with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing
a change in control of our company and might adversely affect the market price of our common stock and the voting and other rights of
the holders of our common stock. We have no current plan to issue any shares of preferred stock.

Anti-Takeover Provisions 

The provisions of the Delaware General Corporation Law (the “DGCL”),
our restated certificate of incorporation and our restated bylaws could have the effect of delaying, deferring or discouraging another
person from acquiring control of our company. These provisions, which are summarized below, may have the effect of discouraging takeover
bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors.
We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer
outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement
of their terms.

Delaware Law 

We are subject to the provisions of Section 203 of the DGCL regulating
corporate takeovers. In general, Section 203 prohibits a publicly held Delaware corporation from engaging in a “business combination”
with an “interested stockholder” for a period of three years following the date on which the person became an interested stockholder
unless:

 

	 	•	prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in the stockholder becoming an interested stockholder; 

 

	 	•	the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, but not the outstanding voting stock owned by the interested stockholder, (i) shares owned by persons who are directors and also officers and (ii) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or 

 

	 	•	at or subsequent to the date of the transaction, the business combination is approved by the board of directors of the corporation and authorized at an annual or special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66.67% of the outstanding voting stock that is not owned by the interested stockholder. 

Generally, a business combination includes a merger, asset or stock
sale, or other transaction or series of transactions together resulting in a financial benefit to the interested stockholder. An interested
stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of interested
stockholder status, did own 15% or more of a corporation’s outstanding voting stock. We expect the existence of this provision to
have an anti-takeover effect with respect to transactions our board of directors does not approve in advance. We also anticipate that
Section 203 may also discourage attempts that might result in a premium over the market price for the shares of common stock held by stockholders.

    2

     

    

 

Restated Certificate of Incorporation and Restated Bylaw Provisions

Our restated certificate of incorporation and our restated bylaws
include a number of provisions that could deter hostile takeovers or delay or prevent changes in control of our company, including the
following:

 

	 	•	Board of Directors Vacancies. Our restated certificate of incorporation and restated bylaws authorize only our board of directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is permitted to be set only by a resolution adopted by a majority vote of our entire board of directors. These provisions would prevent a stockholder from increasing the size of our board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more difficult to change the composition of our board of directors but promotes continuity of management. 

 

	 	•	Classified Board. Our restated certificate of incorporation and restated bylaws provide that our board of directors is classified into three classes of directors, each with staggered three-year terms. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors. See the section entitled “Directors, Executive Officers and Corporate Governance.” 

 

	 	•	Stockholder Action; Special Meetings of Stockholders. Our restated certificate of incorporation provides that our stockholders may not take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a majority of our capital stock would not be able to amend our restated bylaws or remove directors without holding a meeting of our stockholders called in accordance with our restated bylaws. Further, our restated bylaws provide that special meetings of our stockholders may be called only by a majority of our board of directors, the chairman of our board of directors, our Chief Executive Officer or our President, thus prohibiting a stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for stockholders controlling a majority of our capital stock to take any action, including the removal of directors. 

 

	 	•	Advance Notice Requirements for Stockholder Proposals and Director Nominations. Our restated bylaws provide advance notice procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as directors at our annual meeting of stockholders. Our restated bylaws also specify certain requirements regarding the form and content of a stockholder’s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect that these provisions might also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of directors or otherwise attempting to obtain control of our company. 
	 	•	No Cumulative Voting. The DGCL provides that stockholders are not entitled to the right to cumulate votes in the election of directors unless a corporation’s certificate of incorporation provides otherwise. Our restated certificate of incorporation and restated bylaws do not provide for cumulative voting. 

 

    3

     

    

 

	 	•	Directors Removed Only for Cause. Our restated certificate of incorporation provides that stockholders may remove directors only for cause and only by the affirmative vote of the holders of at least two-thirds of our outstanding common stock. 

 

	 	•	Amendment of Charter Provisions. Any amendment of the above provisions in our restated certificate of incorporation requires approval by holders of at least two-thirds of our outstanding common stock. 

 

	 	•	Issuance of Undesignated Preferred Stock. Our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to discourage an attempt to obtain control of us by merger, tender offer, proxy contest or other means. 
	 	•	Choice of Forum. Our restated certificate of incorporation provides that, to the fullest extent permitted by law, the Court of Chancery of the State of Delaware will be the exclusive forum for any derivative action or proceeding brought on our behalf; any action asserting a breach of fiduciary duty; any action asserting a claim against us arising pursuant to the DGCL, our restated certificate of incorporation or our restated bylaws; or any action asserting a claim against us that is governed by the internal affairs doctrine. Our restated bylaws provide that the federal district courts of the United States of America will, to the fullest extent permitted by law, be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act, which we refer to as a Federal Forum Provision. Our decision to adopt a Federal Forum Provision followed a decision by the Supreme Court of the State of Delaware holding that such provisions are facially valid under Delaware law. While there can be no assurance that federal courts or state courts will follow the holding of the Delaware Supreme Court or determine that the Federal Forum Provision should be enforced in a particular case, application of the Federal Forum Provision means that suits brought by our stockholders to enforce any duty or liability created by the Securities Act must be brought in federal court and cannot be brought in state court. While neither the exclusive forum provision nor the Federal Forum Provision applies to suits brought to enforce any duty or liability created by the Exchange Act, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all claims brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Accordingly, actions by our stockholders to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder also must be brought in federal court. Our stockholders will not be deemed to have waived our compliance with the federal securities laws and the regulations promulgated thereunder. Any person or entity purchasing or otherwise acquiring or holding any interest in any of our securities shall be deemed to have notice of and consented to our exclusive forum provisions, including the Federal Forum Provision. These provisions may limit a stockholder’s ability to bring a claim in a judicial forum of their choosing for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. 

Transfer Agent and Registrar 

The transfer agent and registrar for our common stock is VStock Transfer,
LLC.. The transfer agent’s address is 18 Lafayette Place, Woodmere, NY 11598.

Exchange Listing 

Our common stock is listed on the OTCQX Best Market under the
symbol “AUGX.”

    4bicx_ex43.htm

EXHIBIT 4.3
  
 DESCRIPTION OF REGISTRANT’S SECURITIES
 REGISTERED PURSUANT TO SECTION 12 OF THE
 SECURITIES EXCHANGE ACT OF 1934
  
 Set forth below is the description of the common stock, par value $0.001 per share (the “Common Stock”) of BioCorRx Inc. (“we” or “our”). The following description summarizes the most important terms of these securities. This summary does not purport to be complete and is qualified in its entirety by the provisions of our Amended and Restated Articles of Incorporation, as amended (the “Articles”), and our Amended and Restated Bylaws, copies of which have been previously filed with the Securities and Exchange Commission and are incorporated by reference into the Annual Report on Form 10-K for the year ended December 31, 2020. You should refer to our Articles, Bylaws and the applicable provisions of the Nevada Revised Statutes, Chapter 78 (the “Nevada Code”), for a complete description.
  
 The Common Stock is the only class of our securities currently registered under Section 12 of the Securities Exchange Act of 1934. Our Common Stock is quoted on the OTCQB under the symbol “BICX.”
  
 Authorized Common Stock
  
 Our authorized Common Stock consists of 750,000,000 shares.
  
 Dividend Rights
  
 Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our Common Stock are entitled to receive dividends out of funds legally available if our Board of Directors, in its discretion, determines to declare and pay dividends and then only at the times and in the amounts that our Board of Directors may determine.
  
 Voting Rights
  
 Holders of our Common Stock are entitled to one vote for each share held on all matters properly submitted to a vote of stockholders on which holders of Common Stock are entitled to vote. We have not provided for cumulative voting for the election of directors in our Articles. The directors are elected by a plurality of the outstanding shares entitled to vote on the election of directors. On all other matters the affirmative vote of a majority of the voting power of the shares present or represented by proxy at the meeting and entitled to vote on the subject matter constitutes the act of the stockholders, except as otherwise expressly provided by the Nevada Code.
  
 No Preemptive or Similar Rights
  
 Our Common Stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions.
  
 Right to Receive Liquidation Distributions
  
 If we become subject to a liquidation, dissolution or winding-up, the assets legally available for distribution to our stockholders would be distributable ratably among the holders of our Common Stock and any participating preferred stock outstanding at that time, subject to prior satisfaction of all outstanding debt and liabilities and the preferential rights of and the payment of liquidation preferences, if any, on any outstanding shares of preferred stock.
    
 Transfer Agent and Registrar
  
 VStock Transfer LLC is the transfer agent and registrar with respect to the Common Stock.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00325-of-00352.parquet"}]]